Home Cart Sign in  
Chemical Structure| 902135-91-5 Chemical Structure| 902135-91-5

Structure of AT7519 HCl
CAS No.: 902135-91-5

Chemical Structure| 902135-91-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AT7519 HCl is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM and less potent to CDK3 and little active to CDK7.

Synonyms: AT7519 (hydrochloride); AT7519 Hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AT7519 HCl

CAS No. :902135-91-5
Formula : C16H18Cl3N5O2
M.W : 418.71
SMILES Code : O=C(C1=NNC=C1NC(C2=C(Cl)C=CC=C2Cl)=O)NC3CCNCC3.[H]Cl
Synonyms :
AT7519 (hydrochloride); AT7519 Hydrochloride
MDL No. :MFCD14636428
InChI Key :PAOFPNGYBWGKCO-UHFFFAOYSA-N
Pubchem ID :25033099

Safety of AT7519 HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of AT7519 HCl

Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MM1.S cells 2 μM 6 h To investigate the effect of AT7519 on RNA polymerase II elongation in MM1.S cells, results showed that AT7519 significantly reduced the level of elongating RNA polymerase II. PMC4189815
HEK 293T 1 μM AT7519 specifically prevented NBDY phosphorylation at T40 PMC8564862
bone marrow-derived eosinophils (bmEos) 1 µM 48 h To evaluate the effect of AT7519 on the apoptosis of bone marrow-derived eosinophils, results showed that AT7519 increased eosinophil apoptosis. PMC7361019
airway eosinophils 1 µM 48 h To evaluate the effect of AT7519 on the apoptosis of airway eosinophils, results showed that AT7519 increased eosinophil apoptosis. PMC7361019
GAK cells 4 µM 24 h To evaluate the inhibitory effect of AT7519 on the proliferation of GAK cells, the results showed that AT7519 significantly inhibited the proliferation of GAK cells at concentrations higher than 4 µM. PMC6664769
HMV II cells 4 µM 24 h To evaluate the inhibitory effect of AT7519 on the proliferation of HMV II cells, the results showed that AT7519 significantly inhibited the proliferation of HMV II cells at concentrations higher than 4 µM. PMC6664769
MYCN-amplified neuroblastoma cell lines 386 nM 72 h To evaluate the killing effect of AT7519 on MYCN-amplified neuroblastoma cells, results showed that MYCN-amplified cells were more sensitive to AT7519 PMC4645454
Non-MYCN-amplified neuroblastoma cell lines 1227 nM 72 h To evaluate the killing effect of AT7519 on non-MYCN-amplified neuroblastoma cells, results showed that non-MYCN-amplified cells were less sensitive to AT7519 PMC4645454
OSCC cells 1 µM 8 h Inhibition of the CDK2-Rb signaling pathway, reducing the phosphorylation levels of CDK1/2/3 and Rb proteins PMC11097543
MM.1S 0.5 μM 6, 12, 24 h AT7519 induced cell cycle arrest and apoptosis, increasing the proportion of cells in G0/G1 and G2/M phases, and induced apoptosis starting from 12 h. PMC3183744
MM.1S 0.5 μM 1/2, 1, 2, 4, 6 h AT7519 inhibited RNA polymerase II CTD phosphorylation and induced dephosphorylation of RNA polymerase II CTD within 1 h. PMC3183744
MM.1S 0.5 μM 4, 6, 24, 48 h AT7519 inhibited RNA synthesis, with RNA synthesis levels at approximately 50% of control values after 48 h. PMC3183744
U87MG cells 0.4 µM 48 h AT7519 significantly inhibited the proliferation of U87MG cells and induced cell cycle arrest at G1 and G2 phases. PMC9829897
U251 cells 0.4 µM 48 h AT7519 significantly inhibited the proliferation of U251 cells and induced cell cycle arrest at G1 and G2 phases. PMC9829897
GBM38 cells 0.4 µM 48 h AT7519 significantly inhibited the proliferation of GBM38 cells. PMC9829897
GBM60 cells 0.4 µM 48 h AT7519 significantly inhibited the proliferation of GBM60 cells. PMC9829897
Human neutrophils 20 µM To detect CDKi-induced apoptosis, results showed that AT7519 significantly increased the proportion of apoptotic cells. PMC7423924

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice OVA-induced allergic airway inflammation model intraperitoneal injection 30 mg/kg single dose, 24 hours duration To evaluate the therapeutic effect of AT7519 on Mcl-1-overexpressing allergic airway inflammation, results showed that AT7519 significantly reduced BALF cellularity and eosinophils, and increased eosinophil apoptosis. PMC7361019
NOD/SCID mice PDX model Intraperitoneal injection 12 mg/kg Once daily for 14 days To evaluate the inhibitory effect of AT7519 on tumor growth in PDX models, the results showed that AT7519 significantly inhibited tumor growth in PDX models with CDK4 pathway abnormalities. PMC6664769
mice MYCN-amplified neuroblastoma xenograft model intraperitoneal injection 5, 10, 15 mg/kg 5 days on, 2 days off for 3 weeks To evaluate the anti-tumor effect of AT7519 on MYCN-amplified neuroblastoma xenograft model, results showed that AT7519 significantly inhibited tumor growth PMC4645454
BALB/c nude mice OSCC xenograft model Intraperitoneal injection 15 mg/kg Once daily for 7 or 14 days Inhibition of the CDK2-Rb signaling pathway, reducing tumor growth, with enhanced efficacy when combined with PI3K inhibitors PMC11097543
mice human MM xenograft mouse model intraperitoneal injection 15 mg/kg once daily for five days for 2 weeks or three times a week for four consecutive weeks AT7519 inhibited tumor growth, prolonged survival, and did not affect. PMC3183744
Nude mice Subcutaneous xenograft model Intraperitoneal injection 20 mg/kg Once daily for 3 weeks AT7519 significantly reduced the volume and weight of subcutaneous xenograft tumors without significantly affecting the of nude mice. PMC9829897
Mice Acute lung injury model Intraperitoneal injection 30 mg/kg Single dose To evaluate the anti-inflammatory and pro-apoptotic effects of AT7519 in an acute lung injury model, results showed that AT7519 significantly increased the number of apoptotic cells in lung tissue. PMC7423924

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.39mL

0.48mL

0.24mL

11.94mL

2.39mL

1.19mL

23.88mL

4.78mL

2.39mL

References

 

Historical Records

Categories